HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.02930806v1 2/3/563    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Terrault, N. A. Articles by Adey, D. B. Search for Related Content PubMed PubMed Citation Articles by Terrault, N. A. Articles by Adey, D. B.

The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment

Norah A. Terrault^*, and Deborah B. Adey

^* Department of Medicine, Division of Gastroenterology, and Department of Medicine, Division of Nephrology, University of California, San Francisco, San Francisco, California

Address correspondence to: Dr. Norah Terrault, S357, 513 Parnassus Avenue, San Francisco, CA 94143-0538. Phone: 415-476-2227; Fax: 415-476-0659; E-mail: norah.terrault{at}ucsf.edu

Liver disease secondary to chronic hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in dialysis patients and kidney transplant recipients. Evaluation of patients with chronic HCV infection is warranted to determine stage of disease and the need for HCV therapy. Although combination therapy with interferon (IFN) plus ribavirin is the standard of care for chronic HCV infection, IFN monotherapy is recommended in dialysis patients because ribavirin is contraindicated in the presence of renal failure. The goals of pretransplantation HCV therapy are to decrease the risk for progression of HCV-associated liver disease, stabilize renal function in patients with HCV-related glomerulopathy, and prevent development of HCV-associated renal disease after transplantation. Posttransplantation HCV therapy is generally not recommended because of concerns regarding risk for precipitating acute rejection; however, antiviral therapy may be indicated to treat HCV-related glomerulopathy or prevent progression of chronic hepatitis C in patients with more advanced stages of fibrosis. When treatment is required, restored renal function allows use of combination therapy with IFN and ribavirin. Limitations of current HCV therapy include lack of tolerability and suboptimal response rates. New antiviral agents that can be used in dialysis patients (e.g., ribavirin alternatives) and in the posttransplantation setting (e.g., IFN alternatives) are needed to improve outcomes in these populations.

This article has been cited by other articles:

				D. Parsons, R. A. Coward, and A. Woywodt Travel-associated acquisition of hepatitis C-- implications for the renal transplant waiting list Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2104 - 2104. [Full Text] [PDF]